Search for: "Sanofi" Results 1 - 20 of 1,187
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
Sanofi closed its acquisition of Genzyme today: Sanofi said more than 237 million Genzyme shares were tendered in the transaction, representing 89.4 percent of outstanding shares. [read post]
25 Jan 2011, 10:11 am by CorporateAcquisitions MergerLawBlogger
I guess though the talks are still in process, Sanofi is feeling sufficiently comfortable that... [read post]
31 Jan 2011, 4:42 am by By MICHAEL J. DE LA MERCED
Sanofi and Genzyme have agreed on the broad structure of a deal, and Sanofi is likely to raise the price it will pay for Genzyme shares from its current offer of $69. [read post]
8 Feb 2007, 8:17 pm
Lovenox is Sanofi's best-selling drug, with sales of 2.14 billion euros ($2.75 billion) in 2005. [read post]
2 Aug 2012, 2:57 pm by war
In addition to finding Sanofi’s patent infringed, the Full Court affirmed Jagot J’s conclusion that Apotex had no implied licence to reproduce the copyright in Sanofi’s product information documents (PID). [read post]
30 Aug 2010, 5:12 am by By DEALBOOK
Genzyme said Monday it rejected Sanofi's bid of $69 per share, after its board voted unanimously against the offer on Sunday night. [read post]
18 Jul 2012, 4:34 pm by war
Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (No 2) [2012] FCAFC 102 Share on Facebook [read post]
19 Mar 2018, 6:11 am by Robert Kraft
Sanofi head of media relations Ashleigh Koss said the recall only affects “a single lot of the drug, made up of 12,380 syringes produced by Sanofi Genzyme at a plant in Ridgefield, New Jersey. [read post]
25 Sep 2013, 3:07 pm by Mark Zamora
Food and Drug Administration advisory committee on June 13, 2007 urged that the agency reject Sanofi's drug rimonabant, known by the trade names Acomplia and Zimulti, on concern that using it could increase suicidal thinking and depression.http://www.reuters.com/article/2013/09/19/sanofi-settlement-idUSL2N0HF2AK20130919 [read post]
18 Jul 2007, 8:41 am
Forbes noted: "Sanofi-Aventis has not yet been served with a complaint by Novo and our understanding of Novo's allegation is very preliminary,' a spokesman for Sanofi-Aventis told Thomson Financial. [read post]
9 Nov 2011, 9:59 pm by Patent Docs
By Donald Zuhn -- In an appeal decided last month, the Federal Circuit reversed a decision by the District Court for the Southern District of New York awarding prejudgment interest to Plaintiffs-Appellees Sanofi-Aventis, Sanofi-Synthelabo, Inc., and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership ("Sanofi"); affirmed the District Court's denial of a motion for leave to file a supplemental answer, affirmative defenses, and… [read post]
4 Oct 2010, 11:30 am by By STEVEN M. DAVIDOFF
The Deal Professor examines how Sanofi-Aventis could face a long fight with Genzyme over its hostile bid and how it needs to deal with the Genzyme board. [read post]
24 Aug 2010, 5:11 am by By DEALBOOK
Talks between the French pharmaceutical giant Sanofi-Aventis and the American biotech company Genzyme have hit a snag as the two sides seek to agree on a threshhold price that would allow Sanofi to proceed with due diligence, The Wall Street Journal reports. [read post]
26 Dec 2010, 9:59 pm by Patent Docs
The appeal arose from a dispute between Sun and Plaintiffs-Appellees Sanofi-Aventis, Sanofi-Aventis U.S. [read post]
7 Nov 2008, 4:11 am
"Justice Marshall Rothstein concluded that selection patents "encourage improvements" and are therefore legitimate in their own right.In Sanofi's case, the company identified 250,000 possible chemical compounds in its original patent and later developed one into a better drug. [read post]